CD19 and precursor B-cell acute lymphoblastic leukemia: A CD19/CD3 bispecific antibody designed in the BiTE format, blinatumomab, was reported to be effective in patients with B-cell malignances, such as relapsed or refractory B-cell precursor acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma [45,46,47].